Abstract
Introduction: Tuberculosis is a life-threatening disease, and the drugs discovered during the era of 1950 and 1970 are found to be inefficient due to emergent MDR and XDR-TB. Tuberculosis is difficult to treat due to the development of antibiotic resistance. ATP synthase consists of two units, F1 and F0 units. These are present in the cytoplasm and membrane of mitochondria, respectively. F1 unit comprises of a, b, and c subunit while F0 subunit has α, β, γ, δ, ε subunits. Bedaquiline was the first approved ATP synthase inhibitor in 2012 by USFDA.
Methods: Recent literature from 2005-2020 were collected using Pubmed with the keywords ATP synthase inhibitor, bedaquiline derivatives, tuberculosis. The work describing detailed analyses of bedaquiline (BDQ) was included in the current work, and others were excluded.
Results: ATP production occurs via the ATP synthase enzyme, leading to the growth and multiplication of mycobacteria. BDQ inhibits the mycobacterium ATP synthase enzyme, a heteropolymeric complex consisting of two subunits, but it does not interfere with mammalian ATP synthase. Bedaquiline (BDQ) has become a drug of choice in treating MDR-TB and helps in reducing the treatment span. Recently observed triple mutation as wtLeu59A→mtVal59A; wtIle66A→mtMet66A and wtGlu61B→mtAsp61B of ATP synthase led to decrease BDQ binding affinity; thus, researchers are putting efforts for its newer derivative discovery.
Conclusion: ATP synthase inhibitor could be an alternative approach for better treatment of tuberculosis. Herein we discussed the recent advancements in the development of newer analogues of BDQ with its future perspectives.
Keywords: Tuberculosis, MDR-TB, XDR-TB, ATP synthase, Bedaquiline, Inhibitor.
Current Topics in Medicinal Chemistry
Title:Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis
Volume: 21 Issue: 18
Author(s): K.M. Divita and Gopal L. Khatik*
Affiliation:
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research- Raebareli, New Transit Campus, Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow (Uttar Pradesh), 226301,India
Keywords: Tuberculosis, MDR-TB, XDR-TB, ATP synthase, Bedaquiline, Inhibitor.
Abstract:
Introduction: Tuberculosis is a life-threatening disease, and the drugs discovered during the era of 1950 and 1970 are found to be inefficient due to emergent MDR and XDR-TB. Tuberculosis is difficult to treat due to the development of antibiotic resistance. ATP synthase consists of two units, F1 and F0 units. These are present in the cytoplasm and membrane of mitochondria, respectively. F1 unit comprises of a, b, and c subunit while F0 subunit has α, β, γ, δ, ε subunits. Bedaquiline was the first approved ATP synthase inhibitor in 2012 by USFDA.
Methods: Recent literature from 2005-2020 were collected using Pubmed with the keywords ATP synthase inhibitor, bedaquiline derivatives, tuberculosis. The work describing detailed analyses of bedaquiline (BDQ) was included in the current work, and others were excluded.
Results: ATP production occurs via the ATP synthase enzyme, leading to the growth and multiplication of mycobacteria. BDQ inhibits the mycobacterium ATP synthase enzyme, a heteropolymeric complex consisting of two subunits, but it does not interfere with mammalian ATP synthase. Bedaquiline (BDQ) has become a drug of choice in treating MDR-TB and helps in reducing the treatment span. Recently observed triple mutation as wtLeu59A→mtVal59A; wtIle66A→mtMet66A and wtGlu61B→mtAsp61B of ATP synthase led to decrease BDQ binding affinity; thus, researchers are putting efforts for its newer derivative discovery.
Conclusion: ATP synthase inhibitor could be an alternative approach for better treatment of tuberculosis. Herein we discussed the recent advancements in the development of newer analogues of BDQ with its future perspectives.
Export Options
About this article
Cite this article as:
Divita K.M. and Khatik L. Gopal *, Current Perspective of ATP Synthase Inhibitors in the Management of the Tuberculosis, Current Topics in Medicinal Chemistry 2021; 21 (18) . https://dx.doi.org/10.2174/1568026621666210913122346
DOI https://dx.doi.org/10.2174/1568026621666210913122346 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
Addressing the Most Common Causes of Death with Niacin/NAD and Inositol Polyphosphates
The most common causes of death in the world are cardiovascular disease (CVD) and cancer. These are perhaps best addressed by reducing lipodystrophy and blockages with niacin and inositol polyphosphates (e.g., IP6+inositol) respectively when addressing CVD. Niacin serves as a vitamin by virtue of its role as a skeletal precursor ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Peptidomimetic Inhibitors of Cathepsin K
Current Topics in Medicinal Chemistry Detour Cum Distance Matrix Based Topological Descriptors for QSAR/QSPR Part-II: Application in Drug Discovery Process
Letters in Drug Design & Discovery Covid-19 Prevention and Treatment by Targeting Fc-fusion Proteins: An Experience to Fight Emerging Diseases
Current Molecular Medicine Epothilones: From Discovery to Clinical Trials
Current Topics in Medicinal Chemistry Coronavirus (COVID-19) Outbreak: A Test of Viral Muscle Versus the Human Tussle
Applied Clinical Research, Clinical Trials and Regulatory Affairs Recent Progress in the Chemotherapy of Human Fungal Diseases. Emphasis on 1,3-β-Glucan Synthase and Chitin Synthase Inhibitors
Current Medicinal Chemistry Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008
Current Topics in Medicinal Chemistry Synthesis, Docking and Antidiabetic Activity of Some Newer Benzamide Derivatives as Potential Glucokinase Activators
Letters in Drug Design & Discovery Protein Structure Prediction in Structure Based Drug Design
Current Medicinal Chemistry Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
Current Molecular Medicine Microwave Facilitated Discovery of Substituted 1,2,4-triazaspiro[4.5] dec-2-en-3-amines: Biological and Computational Investigations
Current Microwave Chemistry Long Covid and Women’s Health: A Developing Story with Multiple Unknowns for Patients Affected
Current Women`s Health Reviews Interaction of Prolyl Oligopeptidase with α-Synuclein
CNS & Neurological Disorders - Drug Targets Amyloid-β Aggregation Inhibitory and Neuroprotective Effects of Xanthohumol and its Derivatives for Alzheimer’s Diseases
Current Alzheimer Research Tele-Oncology: An Emerging Technology in Developing Countries during the COVID-19 Pandemic
New Emirates Medical Journal Effectiveness of a Lockdown Policy During a Global Pandemic
Current Chinese Science Ion Channels as Important Targets for Antiepileptic Drug Design
Current Drug Targets Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities
Anti-Cancer Agents in Medicinal Chemistry Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products
Current Topics in Medicinal Chemistry